Abstract
Importance: The coronavirus disease 2019 (COVID-19) pandemic has placed unprecedented stress on health systems across the world, and reliable estimates of risk for adverse hospital outcomes are needed. Objective: To quantify admission laboratory and comorbidity features associated with critical illness and mortality risk across 6 Eastern Massachusetts hospitals. Design: Retrospective cohort study using hospital course, prior diagnoses, and laboratory values. Setting: Emergency department and inpatient settings from 2 academic medical centers and 4 community hospitals. Participants: All individuals with hospital admission and positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by PCR testing across these 6 hospitals through June 5, 2020. Exposure: Coronavirus 2 (SARS-CoV-2). Main Outcome Measures: Severe illness defined by ICU admission, mechanical ventilation, or death. Results: Among 2,511 hospitalized individuals who tested positive for SARS-CoV-2 (of whom 50.9% were male, 53.9% white, and 27.0% Hispanic, with mean age 62.6 years), 215 (8.6%) were admitted to the ICU, 164 (6.5%) required mechanical ventilation, and 292 (11.6%) died. L1-regression models developed in 3 of these hospitals yielded area under ROC curve (AUC) of 0.807 for severe illness and 0.847 for mortality in the 3 held-out hospitals. In total, 212/292 (78%) of the deaths occurred in the highest-risk mortality quintile. Conclusions and Relevance: In this cohort, specific admission laboratory studies in concert with sociodemographic features and prior diagnosis facilitated risk stratification among individuals hospitalized for COVID-19. Funding: 1R56MH115187-01 Trial Registration: None
Competing Interest Statement
No funding was received for this study. Dr. Perlis has received consulting fees from Burrage Capital, Genomind, RID Ventures, and Takeda. He holds equity in Outermost Therapeutics and Psy Therapeutics. Dr. McCoy has received research funding from the Stanley Center at the Broad Institute, the Brain and Behavior Research Foundation, National Institute of Mental Health, National Human Genome Research Institute Home, and Telefonica Alfa. Mr. Castro reports no conflict of interest. Dr. Perlis had no role in the editorial review or decision to accept the manuscript for publication.
Funding Statement
No funding was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Partners HealthCare Human Research Committee. No participant contact was required in this study which relied on secondary use of data produced by routine clinical care, allowing waiver of requirement for informed consent as detailed by 45 CFR 46.116. STROBE reporting guidelines for cohort studies were applied.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This manuscript has been updated to conform with journal requirements and to clarify the definition of study outcome variables.
Data Availability
IRB approval does not allow for sharing of data outside of health system
